Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Immunogenicity of Elizaria in PNH
NCT04679103Phase 3Completed
- Sponsor
- Generium
- Start
- May 2018
- Primary completion
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Generium. Started May 2018; status: completed.
02
Drugs
eculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04679103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04679103.